SS Innovations’ SSi Mantra Surgical Robotic System Approved for Telesurgeries in Indonesia and the Philippines
Rhea-AI Summary
SS Innovations (Nasdaq: SSII) announced regulatory approval for telesurgeries using its SSi Mantra surgical robotic system in Indonesia and the Philippines on March 18, 2026. The company also reported surpassing 150 cumulative telesurgeries, with high‑volume sessions in India demonstrating multi‑case capability.
Recent operational highlights include 18 inter‑hospital telesurgeries on February 14, 2026, and a 24‑case telesurgery marathon on December 23, 2025, using the portable SSi MantraAsana console.
Positive
- Regulatory approval for telesurgeries in Indonesia and the Philippines
- Surpassed 150 cumulative telesurgeries, demonstrating clinical adoption
- High‑volume operations: 18 telesurgeries in eight hours on Feb 14, 2026
- Portable SSi MantraAsana console expands settings for telesurgery
Negative
- Clinical use remains primarily concentrated in India, limiting geographic commercialization
Key Figures
Market Reality Check
Peers on Argus
Peer moves appear mixed: within the group, names like NVCR and BBNX showed gains while others such as TNDM declined. Momentum data shows both upside and downside in related medical device stocks, with no consistent direction matching SSII’s slight -0.21% move, pointing to a company-specific narrative.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Full-year earnings | Positive | -5.6% | Reported strong 2025 revenue growth and margin expansion with reduced net loss. |
| Mar 9 | Private placement | Positive | +5.4% | Completed $18.6M capital raise with insider participation to fund global expansion. |
| Jan 13 | Prelim results | Positive | +10.8% | Preliminary Q4 and 2025 figures showed sharply higher revenue and installations. |
| Jan 8 | Leadership change | Neutral | -1.4% | Appointed new Global COO and CFO to support scaling of SSi Mantra platform. |
| Jan 6 | Product update | Positive | +6.5% | Announced new 5-mm instruments to expand use in pediatric and cardiac procedures. |
Positive operating and product news has often led to upside, while strong earnings once saw a negative reaction, indicating occasional divergence between fundamentals and price.
Over the last few months, SS Innovations has highlighted rapid growth in SSi Mantra deployments and revenue, along with new instruments and geographic expansion. Events on Jan 6 and Jan 13 tied product and revenue milestones to double-digit percentage gains. A private placement on Mar 9 supporting growth also saw a positive reaction, while full-year results on Mar 10 drew a negative move, underscoring uneven responses to fundamentally constructive updates.
Market Pulse Summary
This announcement highlights regulatory clearance for SSi Mantra telesurgeries in Indonesia and the Philippines and more than 150 telesurgeries completed, including high-volume sessions of 18 and 24 cases. These data points build on recent disclosures of rapid installation growth and expanding global reach. Investors may track execution at the SMRSC 2026 event, progress toward planned FDA 510(k) and CE milestones, and how utilization trends compare with prior updates.
Key Terms
telesurgeries medical
surgical robotic system medical
AI-generated analysis. Not financial advice.
Company surpasses milestone of 150 cumulative telesurgeries successfully performed with the SSi Mantra
FORT LAUDERDALE, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company’s SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The Company today also announced that more than 150 cumulative telesurgeries have been successfully performed utilizing the SSi Mantra surgical robotic system, primarily in India.
Among recent highlights showcasing the advanced capabilities of the SSi Mantra, a total of 18 inter-hospital telesurgeries were performed between two Indian cities during an eight-hour period on February 14, 2026, including 13 gastric bypass procedures performed by Dr. Mohit Bhandari from Mohak Bariatrics and Robotics in Indore, India and 5 complex gynecological surgeries performed by Dr. Priya Bhave Chittawar from HER Health Hospital in Bhopal, India. All procedures were conducted using the SSi MantrAsana Tele Surgeon Console, a compact self-contained chair-based version of the larger SSi Mantra surgeon command center that enables portability, requires less space, and facilitates the performance of telesurgeries from a wide range of settings, including physician offices.
This feat comes on the heels of a robotic telesurgery marathon that took place from SS Innovation’s headquarters on December 23, 2025, during which nine surgeons utilized the SSi Mantra to perform 24 telesurgeries within a 12-hour period on patients located across multiple locations in India. The telesurgeries consisted of ten different types of procedures, including intricate cardiac surgeries.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “The SSi Mantra surgical robotic system continues to pioneer telesurgery, not merely in concept but in real-world practice and rapidly growing adoption by leading physicians. We are thrilled to receive approval for telesurgeries utilizing the SSi Mantra in two new markets: Indonesia and the Philippines. We also are pleased to surpass the milestone of more than 150 telesurgeries successfully performed with the SSi Mantra, indicating that we are gaining significant traction in enabling state-of-the-art remote surgical care. The SSi Mantra’s advanced telesurgery capabilities empower the cross-sharing of physicians’ expertise and dismantle traditional geographical barriers to care, furthering our mission of driving equitable access to quality healthcare.”
Global Multi-Specialty Robotic Surgery Conference 2026 (“SMRSC 2026”)
On April 9-11, 2026, SS Innovations is hosting SMRSC 2026 in New Delhi, India, where distinguished surgeons, global thought leaders and prominent innovators in robotic and minimally invasive surgery will convene to discuss the shape and future of the field. During the conference, more than 20 live telesurgeries will be performed using the SSi Mantra, spanning multiple specialties and led by top experts in robotic surgery. To register for the conference, please visit: https://ssinnovations.com/SMRSC_2026/register/.
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
FAQ
What did SS Innovations (SSII) announce about telesurgery approvals on March 18, 2026?
How many telesurgeries has SS Innovations (SSII) performed with SSi Mantra as of March 18, 2026?
What were the notable high‑volume SSi Mantra telesurgery sessions in early 2026?
What is the SSi MantraAsana console and how does it affect telesurgery deployment for SSII?
Will SS Innovations showcase SSi Mantra telesurgeries at upcoming events in 2026?
